¹Unidad de Transferencia Genética, Instituto de Oncología 'Ángel H Roffo', Universidad de Buenos Aires, Buenos Aires, Argentina

Correspondence: Dr LME Finocchiaro, Unidad de Transferencia Genética, Instituto de Oncología 'Ángel H Roffo', Universidad de Buenos Aires, Av San Martín 5481, Buenos Aires 1417, Argentina. E-mail: gglikin@bg.fcen.uba.ar

Received 10 June 2007; Revised 14 August 2007; Accepted 15 August 2007; Published online 22 November 2007.

Abstract

We evaluated the safety, efficacy and anti-tumor effects of a surgery adjuvant treatment on canine patients with malignant melanoma. This approach combined suicide gene therapy with a subcutaneous vaccine composed by formolized tumor cells and irradiated xenogeneic cells producing human interleukin-2 and granulocyte–macrophage colony-stimulating factor. The post-surgical margin of the cavity was infiltrated with lipid-complexed thymidine kinase suicide gene coadministrated with ganciclovir. Toxicity was minimal or absent in all patients. With respect to surgery-treated controls (SC), this combined treatment (CT) significantly increased the fraction of patients local disease-free from 6 to 58% and distant metastases-free from 43 to 78% (Fisher's Exact test). In addition, CT significantly improved both SC overall 78 (23–540) and metastasis-free survival 112 (0–467) days to more than 1312 days (respective ranges: 43–1312 and 0–1312) (Kaplan–Meier analysis). In those patients subjected to partial surgery or presenting local recurrence, the efficacy of CT was verified by a 49% of objective responses that averaged 85% of tumor mass loss, while 22% displayed tumor progression as 94% of SC did. Therefore, surgery adjuvant CT controlled tumor growth, delaying or preventing post-surgical recurrence and distant metastasis, significantly extending survival and recovering the quality of life.